Prisons didn’t prescribe many Covid treatments; telemedicine abortion providers prepare for surges

Prisons used just a fraction of the antiviral drugs they were allocated to keep incarcerated people from getting ill or dying of Covid. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by         Prisons didn't prescribe much Paxlovid or other Covid-19 treatments, even when they got the drugs By Nicholas Florko Kobi Wolf/Bloomberg Prisons used just a fraction of the antiviral drugs they were allocated to keep incarcerated people from getting ill or dying of Covid. Read More Telemedicine abortion providers prepare for surges in states where the procedure will remain legal By Olivia Goldhill OLIVIER DOULIERY/AFP via Getty Images Telehealth services are expected to help ease the surge in demand in-person clinics will likely face in states where abortion remains legal. Read More WHO: Nearly 15 million died as a result of Covid-19 in first two years of pandemic By Helen Branswell Dar Yasin/AP The figure is 2.7 times higher than the 5.4 million deaths that governments around the world reported to the WHO for that period. Read More Sponsor content by FISHAWACK HEALTH Omnichannel transformation for the life science industry Across industries, the adoption of digital tools and novel analytics have exploded, so why is biopharma struggling to keep up? In this report, Fishawack Health's Medical, Consulting, and Marketing experts reveal how you can empower your teams to deliver personalized experiences and drive relevant and meaningful engagements across channels. Download the magazine. STAT+: Illumina, maker of a key tool for drug discovery, to try making new drugs itself By Matthew Herper Adobe By entering the drug discovery field itself, Illumina could capture a huge source of revenue. But there are also risks. Read More Listen: Succession at Biogen, surprises at Vertex, & a potential superspreader dinner By Damian Garde and Meg Tirrell and Adam Feuerstein This week, we delve into Biogen's twin announcements that the company is pulling the plug on Aduhelm and replacing its embattled CEO. Read More Opinion: Flawed FDA safety requirements are hamstringing a highly effective treatment for severe schizophrenia By Brian Barnett Alex Hogan/STAT Restrictive federal risk management rules keep many people with schizophrenia from taking a highly effective drug called clozapine. Read More Study uncovers clues to rise in uterine cancer death rates By Carla K. Johnson — Associated Press CDC via AP Over eight years, deaths from the aggressive type rose by 2.7% per year, while deaths were stable for the less aggressive kind. Read More A new 'master regulator' could call the tune for hair cells essential to hearing By Elizabeth Cooney Drs Ignacio García-Gómez and Jaime García-Añoveros The crucial step in mice may be a decade away from helping people, but given widespread loss of hearing as people age, the stakes are high. Read More Opinion: Exploitation in the name of biomedical innovation cannot be tolerated By Anand Kumar Adobe Innovation is part America's cultural and intellectual DNA. But it must be matched with strict checks and balances on accuracy and safety. Read More Thursday, May 5, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser